Ethchlorvynol

Ethchlorvynol

Clinical data
Routes of administration	Oral
ATC code	N05CM08 (WHO)
Legal status
Legal status	Schedule IV
Pharmacokinetic data
Protein binding	35-50%
Identifiers
IUPAC name 1-chloro-3-ethyl-pent-1-en-4-yn-3-ol
CAS Number	113-18-8
PubChem CID	3281
DrugBank	APRD00958
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C7H9ClO
Molar mass	144.598 g/mol

WikiDoc Resources for Ethchlorvynol
Articles
Most recent articles on Ethchlorvynol Most cited articles on Ethchlorvynol Review articles on Ethchlorvynol Articles on Ethchlorvynol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ethchlorvynol Images of Ethchlorvynol Photos of Ethchlorvynol Podcasts & MP3s on Ethchlorvynol Videos on Ethchlorvynol
Evidence Based Medicine
Cochrane Collaboration on Ethchlorvynol Bandolier on Ethchlorvynol TRIP on Ethchlorvynol
Clinical Trials
Ongoing Trials on Ethchlorvynol at Clinical Trials.gov Trial results on Ethchlorvynol Clinical Trials on Ethchlorvynol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ethchlorvynol NICE Guidance on Ethchlorvynol NHS PRODIGY Guidance FDA on Ethchlorvynol CDC on Ethchlorvynol
Books
Books on Ethchlorvynol
News
Ethchlorvynol in the news Be alerted to news on Ethchlorvynol News trends on Ethchlorvynol
Commentary
Blogs on Ethchlorvynol
Definitions
Definitions of Ethchlorvynol
Patient Resources / Community
Patient resources on Ethchlorvynol Discussion groups on Ethchlorvynol Patient Handouts on Ethchlorvynol Directions to Hospitals Treating Ethchlorvynol Risk calculators and risk factors for Ethchlorvynol
Healthcare Provider Resources
Symptoms of Ethchlorvynol Causes & Risk Factors for Ethchlorvynol Diagnostic studies for Ethchlorvynol Treatment of Ethchlorvynol
Continuing Medical Education (CME)
CME Programs on Ethchlorvynol
International
Ethchlorvynol en Espanol Ethchlorvynol en Francais
Business
Ethchlorvynol in the Marketplace Patents on Ethchlorvynol
Experimental / Informatics
List of terms related to Ethchlorvynol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

Along with expected sedative effects of relaxation and drowsiness ethchlorvynol can cause skin rashes, faintness, restlessness and euphoria. Early adjustment side effects can include nausea and vomiting, numbness, blurred vision, stomach pains and temporary dizziness. An overdose is marked by confusion, fever, peripheral numbness and weakness, reduced coordination and muscle control, slurred speech, reduced heartbeat.

It is addictive and after prolonged use can cause withdrawal symptoms including convulsions, hallucinations, and memory loss. Due to these problems, it is unusual for ethchlorvynol to be prescribed for periods exceeding seven days.

Ethchlorvynol is a member of the class of sedative-hypnotic tertiary carbinols, which inludes methylparafynol. It is not a barbituric acid derivative. The systematic name of ethchlorvynol is usually given as ethyl 2-chlorovinyl ethynyl carbinol or 1-chloro-3-ethyl-1-penten-4-yl-3-ol. Its empirical formula is C₇H₉ClO. In the United States Abbott Laboratories used to sell it under the tradename Placidyl. During their heyday, they were known on the street as "jelly-bellies". Since Abbott and Banner Pharmacaps, which manufactured the generic version, discontinued production in 1999, ethchlorvynol is no longer available in the United States.

Ethchlorvynol as it relates to William Rehnquist

Placidyl is the drug prescribed for William Rehnquist as treatment of insomnia after back surgery in 1971, according to FBI files obtained after Rehnquist's death. Before he was hospitalized in 1981, court employees noticed that Rehnquist's speech was slurred and that he seemed to be having mental lapses. The hospital doctors took him off the medication, causing withdrawal symptoms, which included hallucinations.

One of the physicians who treated Rehnquist for Placidyl withdrawal, according to the FBI files, described auditory hallucinations in the form of voices discussing him outside his hospital room. At one point the Justice tried to flee the hospital in his pajamas, specifically because of the mistaken belief that the CIA was plotting against him.

References

• PubChem Substance Summary: Ethchlorvynol National Center for Biotechnology Information. Accessed 1 September 2005 (UTC)
• Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations Food and Drug Administration. Accessed 12 December 2005 (UTC)
• FBI: Rehnquist withdrew from painkillers (CNN.com) Accessed 5 Jan. 2007

Template:Sedative